BiomX Q3 net loss $6.8M; BX004 Part 1 results expected Q1 2023, cash through mid-2024

BiomX Inc.

2022-Q3 EPS reported $0.75

Cash $41.5M as of Sep 30, 2022; cash runway through at least mid-2024.
Net loss $6.8M vs $10M in Q3 2021; R&D expenses $3.5M (down from $6.6M) due to restructuring.
BX004 Phase 1b/2a Part 1 results expected Q1 2023; Part 2 results Q3 2023.
CF Foundation equity award up to $5M; second $2M tranche upon Part 1 dosing completion.
Published Cell paper on phage proof-of-concept for inflammatory bowel disease.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BiomX Inc. reported the third quarter ended September 30, 2022 results: net income $6.8 million.

Period: the third quarter ended September 30, 2022
Net income: $6.8 million
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2022 was $6.8 million, compared to $10 million for the same period in 2021.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-070348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.